Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Non-inferiority With Participants Diagnosed With Primary Knee OA (GLACIAL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Male and female patients meeting all the following criteria will be enrolled in the study:~1. Aged ≥ 40 years.~2. Clinical and radiological diagnosis of primary (idiopathic) arthrosis of knee according to the criteria of the American College of Rheumatology (ACR).~3. Kellgren and Lawrence radiological classification of degree 2 or 3 in x-ray of knee-target obtained in 3 months prior to the screening visit of the study.~4. Presence of painful symptoms in the target knee in the last 3 months due to osteoarthritis.~5. Visual analogue scale for evaluation of the pain of osteoarthritis of knee by the research participant in the screening visit ≥ 40 mm~6. Average score ≥ 40 mm in the subscale of pain (from 0 to 100 mm) in the target knee of the questionnaire Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), in the randomization visit.~7. Functional class ACR from I to III.~8. Signing the Informed Consent Form (ICF) before the performance of any study procedure.~Exclusion Criteria:~Patients meeting at least one of the following criteria will be excluded from the study:~1. Diagnosis of septic arthritis, inflammatory arthritis (as rheumatoid arthritis), gout, pseudogout, Paget's disease, dysplasias or congenital joint abnormalities.~2. Presence of inflammatory signals (edema, erythema or joint effusion) in the target knee, considered to be clinically significant by investigator.~3. Serious target knee joint misalignment, defined by investigator.~4. Predominantly patellofemoral Osteoarthritis in the target knee.~5. Historical of severe trauma or surgery (including arthroscopy) in the target knee in the 6 months before the screening visit.~6. Planned Surgery to the target knee~7. Symptomatic Osteoarthritis of the ipsilateral hip.~8. Use of non-steroidal anti-inflammatory, dipyrone and opioid analgesics or narcotics from the screening visit, or a washout period for these medicines less than those defined by the Protocol, before the randomization visit .~9. Oral Glucocorticoids, intravenously or intramuscularly in the 30 days prior to the screening visit.~10. Intraarticular corticosteroid Injection and/or hyaluronic acid in the target knee in 6 months prior to the screening visit.~11. Use of the following drugs in the periods described below, before the screening visit:~    1. Diacerein, chloroquine or soybean and avocado unsaponifiables extracts in the last 3 months.~   2. Duloxetine hydrochloride in the last 30 days.~   3. Glucosamine Sulphate and/or chondroitin sulfate in the last 6 months.~   4. Strontium ranelate for the past 6 months.~12. Historical of allergy or intolerance to treatment of the study or to paracetamol.~13. Physiotherapy or irregular practice of physical activity beginning in the 3 months prior to the screening visit.~14. Diagnosis of fibromyalgia, collagenosis or significative vascular/neurologica diseases in lower limbs that may confuse the analysis of the study.~15. Body mass index ≥ 40 kg/m2.~16. Need to use cane, crutches or a walker.~17. Presence of infectious hepatitis active or history of hepatitis medicinal products.~18. Results of ALT, AST and total bilirubin and fractions above the upper limit of normal.~19. Serum creatinine level above the upper limit of normal.~20. Fasting blood glucose \> 110 mg/dL or glycated hemoglobin \> 6.5%.~21. Use of anticoagulants.~22. Consumption of alcohol more than one dose a day (women) or two doses a day (men).~23. Presence of serious diseases or not controlled.~24. Planned surgery to occur during the period of participation in the study.~25. Presence of pregnancy or breastfeeding.~26. Women of childbearing potential must agree to use highly effective contraception.~27. Participation in a clinical trial protocol within the previous 12 months unless, at the investigator's discretion, his or her participation may imply a direct benefit for the participant.~28. Presence of any condition which, at the investigator's discretion, may consider the participation of the patient inadequate for the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glucosamine and chondroitin sulfate combination (Eurofarma) (Type: EXPERIMENTAL): Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Eurofarma Laboratórios S.A., administered once a day for 24 weeks.
- Glucosamine and chondroitin sulfate combination (Zodiac) (Type: ACTIVE_COMPARATOR): Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Zodiac Produtos Farmacêuticos S.A. (Condroflex®), administered once a day for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).